APEIRON Biologics: Patient recruitment completed in Phase II COVID-19 Clinical Trial of APN01

Results of the double-blind, placebo-controlled trial expected in Q1 2021 Preparations for rolling Marketing Authorization Application in Europe commenced Trial results to confirm unique triple mode of action to prevent infection, organ injury and inflammation Press release (EN) | Presseaussendung (DE)
December 4, 2020
View the Post

APEIRON Biologics AG and Domainex Ltd announce the expansion of their partnership to progress targeted cancer immune therapy drug discovery

Integrated lead optimisation to advance APEIRON’s Cbl-b inhibitor development programme APN431 Inhibitors discovered at Domainex via virtual and fragment screening Press release (EN) | Presseaussendung (DE)
November 9, 2020
View the Post

APEIRON Biologics AG strengthens shareholder structure and Supervisory Board with international anchor investor

British investor consortium Franklin Road Ltd. increases its stake in APEIRON Biologics significantly to over 13% Extraordinary General Meeting elects Edward Charles MA, Managing Director of Franklin Road Ltd., as a new Supervisory Board member Press release (EN) | Presseaussendung (DE)
October 15, 2020
View the Post